Table 2_Hypomethylating therapy mitigates acute allograft rejection in a murine lung transplant model.docx

IntroductionAcute cellular rejection of transplanted lung allografts involves activated cytotoxic T cells and reduced Regulatory T (Treg) cell function. Calcineurin inhibitors, the cornerstone of immunosuppressive regimens, suppress T cell cytotoxicity but inhibit Treg proliferation. The DNA hypomethylating agent decitabine (DAC) can abrogate T cell cytotoxicity while stimulating Treg proliferation.
MethodsWe sought to determine the effects of DAC treatment in a murine MHC-mismatched orthotopic lung transplant model.
ResultsRescue treatment with DAC maintains lung allograft gross and histologic integrity with a reduction in cytotoxic T cell responses. CD4+FoxP3+ T cell depletion in Foxp3DTR mice exacerbated rejection lung injury compared to CD4+FoxP3+ T cell sufficient mice and failed to abolish the protective effect of DAC in this model. The protective effect of DAC was associated with a reduction in cytokine production from host T-cells.
DiscussionDecitabine could offer a new line of treatment for acute lung allograft rejection, in part via its effects on Tregs.